- Lobbying
- Lobbying by Agios Pharmaceuticals, Inc.
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
T.J. Petrizzo | n/a |
Tricia Barrentine Guay | n/a |
Lindsey Ledwin | n/a |
Phil Bond | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Defense - Dept of (DOD)
Health & Human Services - Dept of (HHS)
Natl Institutes of Health (NIH)
Type of Issue
Health Issues
Budget
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Defense - Dept of (DOD)
Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues
Budget
Q2 Report
Q1 Report
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Budget
Defense
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Budget
Defense
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Defense
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Natl Institutes of Health (NIH)
Type of Issue
Budget
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Natl Institutes of Health (NIH)
Health & Human Services - Dept of (HHS)
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. Senate
Health & Human Services - Dept of (HHS)
Natl Institutes of Health (NIH)
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. Senate
Type of Issue
Registration
Issue(s) they said they’d lobby about: Advance federal funding for research into cancer metabolism and the development of therapies that disrupt the growth and survival of cancer cells..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate